Document is current
Any future updates will be listed below
-
Authors
Blombery, Piers https://orcid.org/0000-0002-9902-0022
Chatzikonstantinou, Thomas https://orcid.org/0000-0003-4105-1253
Gerousi, Marina
Rosenquist, Richard https://orcid.org/0000-0002-0211-8788
Gaidano, Gianluca https://orcid.org/0000-0002-4681-0151
Pospisilova, Sarka
Roberts, Andrew W.
Birkinshaw, Richard W. https://orcid.org/0000-0003-1825-0182
Rossi, Davide
Scarfo, Lydia https://orcid.org/0000-0002-0844-0989
Seymour, John F.
Stilgenbauer, Stephan https://orcid.org/0000-0002-6830-9296
Wiestner, Adrian
Woyach, Jennifer A. https://orcid.org/0000-0002-3403-9144
Brown, Jennifer R.
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Stamatopoulos, Kostas https://orcid.org/0000-0001-8529-640X
,
-
Funding
Funding for this research was provided by:
The Wilson Centre for Blood Cancer Genomics The Snowdome Foundation
The Swedish Research Council and Radiumhemmets Forskningsfonder
Associazione Italiana per la Ricerca sul Cancro (AIRC) Foundation Associazione Italiana per la Ricerca sul Cancro (AIRC) Foundation Milan
The intramural research program of the NHLBI, NIH
Leukemia & Lymphoma Society
- License Information
-
More Information
Article History
Received: 4 February 2025
Revised: 9 May 2025
Accepted: 30 May 2025
First Online: 24 June 2025
Competing interests
: PB - Consultancy/advisory role and honoraria from AbbVie, Adaptive Biotechnologies, AstraZeneca and Roche Diagnostics; speakers bureau participation for AstraZeneca and Janssen. TC - Honoraria from AbbVie, AstraZeneca and BeiGene. GG - Advisory Boards/Speaker’s Bureau and honoraria from AbbVie, AstraZeneca, BeiGene, Hikma, Incyte, Johnson & Johnson, Lilly. LS - Honoraria from AbbVie, AstraZeneca, BeiGene, Johnson&Johnson, Lilly, Merck. SS - Advisory board/Research support/Travel support/Speaker fees from AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Galapagos, Gilead, GSK, Hoffmann-La Roche, Janssen, Lilly, Novartis, Sunesis. AR - Inventor on a patent related to venetoclax; Employee of Walter and Eliza Hall Institute which received venetoclax-related milestone and royalty income, which is shared with employees; AbbVie, research funding for previous research; Janssen: research funding for research. RB - Employee of Walter and Eliza Hall Institute which received venetoclax-related milestone and royalty income, which is shared with employees. AW - Research support from Pharmacyclics LLC, an AbbVie Company, Acerta Pharma, a member of the AstraMI-Zeneca group, Merck, Nurix, Verastem and Genmab. RR - Honoraria from AbbVie, AstraZeneca, Illumina, Janssen, Lilly and Roche. JAW - Consultancy for AbbVie, AstraZeneca, Beigene, Genentech, J&J, Loxo/Lilly, Merck, and Newave. PG - Honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Genmab, Johnson & Johnson, Lilly/LoxoOncology, MSD, Roche; research funding from AbbVie, AstraZeneca, BMS, Johnson & Johnson, Lilly/LoxoOncology, MSD. KS - Research support from AbbVie, AstraZeneca, Janssen, Novartis, Roche; honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Lilly and Janssen.
